Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00888628 · ClinicalTrials.gov registry record · Phase 1
Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00888628: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00888628 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00888628, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of the study is to learn if islet transplantation is an effective treatment for Type 1 diabetes in people who have had a kidney transplant. The primary objectives of the study are: \- To set up islet transplantation in patients who have had a kidney transplant and who are using an immunosuppressive regimen that works The Secondary objective of the study is: * To find out if successful islet transplantation leads to improved metabolic control and reduced renal complication from diabetes
Interventions
- DRUG Etanercept
- BIOLOGICAL Purified Pancreatic Islets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-05 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00888628
The ClinicalTrials.gov registry entry for NCT00888628 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Etanercept is the first listed.
NCT00888628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00888628 about?
NCT00888628 is a clinical study titled "Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients". The purpose of the study is to learn if islet transplantation is an effective treatment for Type 1 diabetes in people who have had a kidney transplant. The primary objectives of the study are: \- To set up islet transplantation in patients who have had a kidney transplant and who are using an immu...
What is the current status of trial NCT00888628?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2009-05. Estimated completion is 2016-08.
What interventions are being tested in trial NCT00888628?
The interventions under investigation include: Etanercept (DRUG), Purified Pancreatic Islets (BIOLOGICAL).
Who is sponsoring clinical trial NCT00888628?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.